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Summary 
Since the discovery of endothelin-1 in 1988, the main components of the signalling pathway 
have become established comprising three structurally similar endogenous twenty-one amino 
acids peptides, ET-1, ET-2 and ET-3, that activate two G-protein coupled receptors, ETA and 
ETB..  Our aim in this review is to highlight the recent progress in endothelin research.  The 
endothelin-like domain peptide, corresponding to prepro-ET-193-166, has been proposed to be 
co-synthesised and released with ET-1, to modulate the actions of the peptide.  ET-1 remains 
the most potent vasoconstrictor in the human cardiovascular system with a particularly long 
lasting action.  To date, the major therapeutic strategy to block the unwanted actions of ET in 
disease, principally in pulmonary arterial hypertension, has been to use antagonists that are 
selective for the ETA receptor (ambrisentan) or that block both receptor subtypes (bosentan).  
Macitentan represents the next generation of antagonists, being more potent than bosentan, 
with longer receptor occupancy and it is converted to an active metabolite; properties 
contributing to greater pharmacodynamic and pharmacokinetic efficacy.  A second strategy is 
now being more widely tested in clinical trials and uses combined inhibitors of endothelin 
converting enzyme and neutral endopeptidase such as SLV306 (daglutril).  A third strategy 
based on activating the ETB receptor, has led to the renaissance of the modified peptide 
agonist IRL1620 as a clinical candidate in delivering anti-tumour drugs and as a 
pharmacological tool to investigate experimental pathophysiological conditions.  Finally we 
discuss biased signalling, epigenetic regulation and targeting with monoclonal antibodies as 
prospective new areas for endothelin research. 
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Introduction 
Since the discovery of endothelin-1 (ET-1) in 1988 (Yanagisawa, et al., 1988, Inoue et al., 
1989) the components of the ET signalling pathway have become established, comprising 
three structurally similar endogenous twenty-one amino acids peptides, ET-1, ET-2 and ET-3, 
that activate two G protein-coupled receptors, ETA (Arai et al., 1990) and ETB (Sakuri, et al., 
1990).  In humans ET-2 differs from ET-1 by only two amino acids, whereas ET-3 differs by 
six amino acids representing more substantial changes.  ET-3 is the only isoform that can 
distinguish between the two receptor sub-types, having a similar potency at the ETA receptor 
as ET-1 and ET-2, but much lower affinity than these isoforms for the ETB sub-type (Figure 
1).  Structurally, ETs are unusual amongst the mammalian peptides in possessing two 
disulphide bridges.  This feature is shared by the sarafotoxins, a family of peptides that were 
isolated from snake venom in the same year as the discovery of ET-1 (Takasaki et al., 1988) 
and that provided the first selective agonist at the ETB receptor, sarafotoxin S6C (Williams et 
al., 1991). 
A number of features of the ET signalling pathway are unusual compared with other 
peptidergic systems and these continue to intrigue investigators, with over a thousand ET-
related papers still published each year.  ET-1 is the most abundant isoform in the human 
cardiovascular system, predominantly released from endothelial cells to cause potent and 
unusually long lasting vasoconstriction that may persist for many hours.  ET-1 is a key 
mediator in regulating vascular function in the majority of organs systems balanced by 
opposing vasodilators, particularly nitric oxide, prostacyclin and endothelium derived 
hyperpolarising factor.  Endothelial cell dysfunction occurs in pathophysiological conditions 
such as pulmonary arterial hypertension (PAH) and is associated with loss of these dilators 
and increased synthesis of ET.  The consequence of this is vasoconstriction, proliferation of 
multiple cell types particularly vascular smooth muscle, fibrosis and inflammation; processes 
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associated with vascular remodelling.  In disease the deleterious actions of ET in the 
vasculature are mainly mediated by the ETA receptor, whereas ETB activation results in many 
of the beneficial effects of the peptide that frequently act as a regulatory counterbalance 
(Davenport and Maguire, 2006).  The formation of the disulphide bridge in the ET peptides 
blocks the N-terminal amino acid conferring resistance to enzymatic degradation in plasma: 
the internalization by ETB scavenging receptors is therefore particularly important for 
termination of the ET signal in health and disease. 
The major therapeutic strategy (Figure 1) to block the unwanted actions of ET in disease 
has been to use antagonists of ETA or both receptor sub-types (Palmer, 2009) with the first 
clinical application being bosentan in PAH (Rubin et al., 2002).  More recently, a second 
strategy has started to be more widely tested in clinical trials using inhibitors of endothelin 
converting enzymes, ECE-1 (Xu et al., 1994) and ECE-2 (Emoto and Yanagisawa, 1995), the 
major synthetic pathway of ET (Figure 1) at least in the human vasculature (Russell and 
Davenport, 1999a, b).  A third emerging strategy based on biosimilar agonists at the ETB 
receptor (molecules similar but not identical to the endogenous ligand) has led to the 
renaissance of IRL1620 as a clinical candidate in delivering anti-tumour drugs and in other 
pathophysiological conditions such as cerebral ischaemia. 
The aim of this focused IUPHAR review is to highlight recent progress and some 
surprising new discoveries in the pharmacology of the ET system.  The following are 
recommended for more detailed information on specific ET research areas including the heart 
(Kelland and Webb, 2006; Kirby et al.,  2008; Kohan et al.,  2012; Ohkita et al.,  2012; 
Vignon-Zellweger et al.,  2012; Drawnel et al.,  2013), renal (Kohan et al.,  2011a, b; Dhaun 
et al., 2011, 2012; Hyndman and Pollock, 2013), hypertension (Rautureau and Schiffrin, 
2012; Speed and Pollock, 2013), PAH (Pernow et al.,  2012; Rubin, 2012; Liu et al. 2013), 
cancer (Bagnato et al.,  2011; Said and Theodorescu, 2012; Rosanò et al., 2013b), 
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atherosclerosis and diabetes (Pernow et al., 2012). 
ET Peptides 
Evidence for a new ET peptide: the endothelin-like domain peptide (ELDP) 
The ELDP has been recently identified as a peptide corresponding to prepro-ET-193-166 
(Yuzgulen et al., 2013) immediately adjacent to the gene sequence encoding big ET-1.  The 
74 amino acid peptide has been detected by high performance liquid chromatography and 
specific double recognition site immunoassays in conditioned media from two cell lines, 
endothelial (EA.hy 926) and epithelial (A549), as well as from primary cell cultures of 
human aortic endothelial cells that are known to secrete ET-1.  In the aortic endothelial cells, 
the peptide was co-synthesised and co-released with ET-1.  Plasma levels in untreated 
patients were 6.5 pmol l
-1
 which compares with typical basal levels of immunoreactive ET-1 
of 5 pmol l
-1 
(Davenport et al.  1990).  Levels of ELDP were significantly elevated in heart 
failure patients suggesting a potential use as a bio-marker.  While no effect was observed on 
blood pressure in the anaesthetised rat, intriguingly ELDP significantly increased the duration 
of the pressor response of ET-1 (0.3 nmol kg
-1
, likely to be a sub-maximal dose).  Pre-
treatment of rat mesenteric arteries with 10 nM ELDP also potentiated a sub-maximal 
response of ET-1 by five fold (Yuzgulen et al., 2013).  It is not unexpected that a second 
peptide sharing a cleavage site with ET-1 would also be co-released, but it is intriguing that 
the peptide was able to potentiate ET-1 responses in vitro and in vivo.  It is not yet reported 
using saturation or competition binding experiments whether ELDP binds directly to ET 
receptors, binds to an allosteric site or whether the peptide modulates ET responses by other 
mechanisms.  Intriguingly, ELDP encompasses the sequence of the putative ‘endothelin-like 
peptide’ corresponding to prepro-ET-1109-123 proposed in the original Nature paper by 
Yangisawa et al. (1988).  Eight out of fifteen residues in the corresponding sequence in ET-1 
are identical and the four Cys residues are perfectly conserved and flanked by dibasic pairs 
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that are recognised by endopeptidase processing enzymes, to yield a cleaved peptide.  
However, a synthetic peptide corresponding to this sequence was devoid of agonist or 
antagonist activity against ET-1, in vascular preparations (Cade et al., 1990). 
 
Global knock-out of ET-2 gene reveals distinct phenotype compared with ET-1/ETA and ET-
3/ETB gene deletions 
ET-1-deficient homozygous mice die at birth of respiratory failure which is secondary to 
severe craniofacial and cardiovascular abnormalities.  ETA receptor and ECE-1 knockout 
mice have similar morphological abnormalities (Kurihara et al. 1994; Clouthier et al. 1998; 
Yanagisawa et al. 1998,).  The phenotype is similar to a spectrum of human conditions, 
CATCH 22 (Cardiac anomaly, Abnormal face, Thymic hypoplasia, Cleft palate, 
Hypocalcemia, chromosome 22 deletions) and established the importance of the ETA/ET-1 
signalling system for cardiovascular and craniofacial development.  ET-3 and ETB gene 
deletions exhibit a different and non-overlapping phenotype to ET-1/ETA-deficient animals.  
They are viable at birth and survive for up to eight weeks, but display aganglionic 
megacolon, as a result of absence of ganglion neurons, together with a pigmentary disorder in 
their coats (Baynash et al., 1994; Hosoda et al., 1994).  In these mice, enteric nervous system 
precursors and neural crest-derived epidermal melanoblasts fail to colonise the intestine and 
skin.  This phenotype resembles Hirschsprung's disease in man. 
Deleting genes encoding all the key molecules, ET-1, ET-3, ETA, ETB, ECE-1 and ECE-
2 has been accomplished in mice generating important information about their effect on 
phenotype. The deleting the gene for ET-2 has now been reported.  The physiological role of 
ET-2 has been puzzling.  It had been assumed that the actions of ET-2 would be similar, if 
released, to the more widely distributed and abundant ET-1.  Current antagonists block both 
ET-2 and ET-1 with the same potency and are not yet able to distinguish the actions of these 
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peptides. 
A key advance in the field was the generation by Chang et al. (2013) of a global ET-2 
gene knock-out mouse, which surprisingly exhibited a distinct phenotype to global ET-1 or 
ET-3 gene deletions.  These mice showed severe growth retardation, internal starvation 
characterised by hypoglycemia, ketonemia, and increased levels of starvation-induced genes.  
Mice were profoundly hypothermic and the median lifespan could be significantly extended 
by housing in a warm environment.  The intestine was morphologically and functionally 
normal, which was unexpected as murine ET-2 (see Ling et al,. 2013), also known as 
vasoactive intestinal contractor or VIC, is present throughout the gastrointestinal tract 
suggesting, in this tissue at least, in the absence of ET-2, ET-1 continues to mediate 
signalling.  In agreement, intestinal epithelium-specific ET-2 knockout mice showed no 
abnormalities in growth and survival.  In marked contrast, dramatic changes were observed in 
lung morphology and function.  Mice had breathing difficulties after the first week exhibiting 
enlarged air spaces with substantial simplification of lung alveolar structure, larger lung 
capacities leading to abnormally elevated carbon dioxide (hypercapnia) and deficiency of 
oxygen (hypoxaemia) in the blood.  Hypothermia and lung dysfunction might not be specific 
but may be due to a secondary effect of internal starvation due to ET-2 deficiency.  However, 
it is possible that these studies identify an important function for ET-2 in the pulmonary 
system.  The authors showed that mRNA encoding ET-2 was only present in epithelial cells 
whereas receptor mRNA was mainly present in mesenchyme, consistent with a paracrine 
function for ET-2 in the lung. 
 
Pharmacological significance: Is ET-2 the inducible isoform? 
The dramatic effects on the lung suggest a crucial role for ET-2 at birth, at least in mice.  The 
lungs, and potentially the heart, remain major therapeutic targets for ET antagonists in 
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humans in the treatment of PAH.  In rodents ET-2 was less widely distributed that ET-1, 
mainly found in heart, lung, ovary, stomach and all regions of the intestine (De La Monte et 
al.,  1995; Takizawa et al.,  2005).  ET-2 expression in human tissue was similar, being 
present in human heart (Plumpton et al.,  1996b), lung  (Marciniak et al., 1992), kidney 
(Karet and Davenport, 1996), vasculature, (Howard et al.,  1992) intestine and ovaries 
(Palanisamy et al., 2006) but has not been investigated in pathophysiological tissue.   In 
humans alternatively spliced mRNA variants encoding ET-2 have been detected with a 
specific pattern of distribution in various tissues.  Some of these variants contain sites for the 
post-transcriptional processing of preproET-2 into mature ET-2 which may be altered in a 
tissue specific manner (O'Reilly et al., 1993).  The most well established model of spatial and 
temporal ET-2 signalling is in the ovary, a highly vascular tissue, which undergoes cyclic 
changes as follicles grow, rupture and transform into corpora lutea and eggs are periodically 
released (Ko et al., 2012).  In rats, low levels of ET-1 are constitutively expressed throughout 
the ovulatory cycle, whereas ET-2 is induced transiently at much higher concentrations 
during the period of ovulation to luteal phases (Ko et al., 2006).  ET-2 is expressed in the 
granulosa cells of periovulatory follicles but not during other stages of follicular 
development.  In mice, induced superovulation results in a dramatic increase in ET-2 mRNA 
expression (Palanisamy et al., 2006).  ET-2 expression surged in response to gonadotropin 
and quickly declined by 13 h, which coincided with the time of follicular rupture.  Crucially, 
both ET receptor sub-types are present and their ratio does not seem to change.  Thus the ET-
2 gene appears to be switched on only when increased levels of ET are required, with ET-2-
mediated contraction being the final signal facilitating ovulation (Ling et al., 2013). 
ET-1 signalling is well established in neural crest migration.  In the developing mouse 
retina constitutive over-expression of ET-2 affects vascular development by inhibiting 
endothelial cell migration across the retinal surface and subsequent endothelial cell invasion 
 10 
into the retina, an action mediated by ETA receptors.  Interestingly, over-expression is 
spatially localised as it has no obvious action on vascular structures in brain or skin (Rattner 
et al., 2013).  Constitutive over-expression of ET-2 signalling also protected photoreceptors 
from light damage (Braunger et al.,  2013).  Similarly, Bramall et al, (2013) found expression 
of ET-2 mRNA was greatly increased in the photoreceptors of mouse models of inherited 
photoreceptor degeneration and using the global ET-2 knock-out mice showed increased ET-
2 expression is protective of the mutant photoreceptors. 
 
The case for re-evaluating the role of ET-2  
Targeting the ET-2 gene in mice provides compelling evidence that while both ET-1 and ET-
2 can co-exist in the same tissue compartments, there is a critical but distinct ET-2 pathway.  
A key role has now been established for ET-2 in ovarian physiology.  This may be 
accomplished at the level of gene expression, but differences may also exist in peptide 
synthesis by ECEs and chymase, which may allow the two ET peptide pathways to be 
distinguished pharmacologically and become separate drug targets.  Additionally, 
pharmacological differences have been identified, for example ET-2 dissociates from 
receptors much more rapidly than ET-1 and higher affinity has been reported for example in 
brain (Ling et al., 2013).  Detailed studies comparing  rat mesenteric resistance and basilar 
arteries demonstrated that ET-1 and ET-2 initiate and maintain vasoconstriction by different 
downstream mechanisms raising the prospect of ‘biased signalling’ mediated by two 
structurally different agonists activating the same receptor (Compeer et al., 2013). 
 
Potential new therapeutic strategies exploiting ETB receptor agonists 
The pharmacological rationale for this strategy is that ET-1 topically released from 
endothelial cells also interacts with endothelial cell ETB receptors.  The importance of this 
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counter regulatory pathway has been underestimated to date.  Endothelial cells line the 
vasculature of every organ and tissue in the body that receives a blood supply.  Although the 
cells represent ~1% of the weight of the vessel wall, they have a combined mass comparable 
to some endocrine glands.  Crucially, ET-1 feeding back onto endothelial receptors to release 
nitric oxide not only limits ETA mediated vasoconstriction by stimulation of vascular cyclic 
GMP, but also limits further ET-1 release.  Thus in the vasculature, nitric oxide and other 
dilators are crucial in balancing the ET system, but these may be reduced or absent in 
pathophysiological conditions. 
ET-1
+/-
 heterozygous mice developed elevated blood pressure and mild hypertension, rather 
than the fall in blood pressure that might have been expected.  Partial deletion of the gene 
allows survival and produced lower levels of ET-1 in plasma and lung tissue than wild-type 
(Kurihara et al., 1994).  These results suggest that ET-1 has an essential physiological role in 
cardiovascular homeostasis.  Low levels promote vasodilatation whereas higher and 
pathophysiological concentrations of ET-1 increase blood pressure and total peripheral 
vascular resistance.  While ETA selective antagonists such as BQ123 (Ihara et al., 1992) 
cause the expected vasodilatation in humans (Haynes and Webb, 1994),  the ETB selective 
antagonist BQ788 (Ishikawa  et al., 1994) caused systemic vasoconstriction in healthy 
volunteers, showing that the main consequence of activation of endothelial ETB receptors by 
tonically secreted ET-1 was the physiological basal release of nitric oxide (Love et al. 2000).  
In agreement, initial vasodilatation can be detected in the human forearm vascular bed 
following infusion of low concentrations of ET-1 whereas higher doses caused sustained 
vasoconstriction (Kiowski et al, 1991). A contribution to vasoconstriction may also be the 
result of ET-1 occupancy of the clearance ETB receptors causing an ETA-mediated 
vasoconstriction.  
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ETB agonists in chemotherapy: IRL1620 
ET-1 acting on ETA receptors has been proposed to stimulate cell proliferation, migration, 
invasion, osteogenesis and angiogenesis in several cancers.  New vessels forming in tumours 
are characterised by high densities of ETA receptors in smooth muscle, for example in 
glioblastoma multiforme in the brain (Harland et al., 1998).  Conversely, ETB receptors may 
oppose tumour progression by promoting apoptosis and clearing ET-1 (Bagnato et al., 2011; 
Rosanò et al., 2013b).  The strategy of stimulating ETB receptors to cause transient 
vasodilatation is being developed to increase the penetration of cytotoxic anti-tumour agents 
into tumours and to minimise the concentration in healthy tissue. 
IRL1620 was originally developed as a tool compound (Takai et al., 1992).  The N-
terminus has an N-sucinyl modification, likely to beneficially reduce metabolism by non-
specific peptidases, but it is not orally active and requires injection.  Despite these 
unpromising pharmacokinetic features it is being used in vivo and has emerged as a possible 
clinical candidate in improving the delivery of drugs to tumours.  IRL1620 infused into rats 
improved the efficacy of doxorubicin and 5-flurouracil by significantly increasing the amount 
of drug in tumours in rat models of prostrate and breast cancer.  In addition, radiation induced 
reduction in tumour volume was enhanced, suggesting IRL1620 can significantly increase the 
efficacy of radiotherapy in the treatment of solid tumors.  The results suggest that for a given 
dose of drug the efficacy in reducing the tumour could be improved (Gulati et al., 2004, 
2012; Rajeshkumar et al., 2005a, b; Lenaz  et al., 2006; Rai  et al., 2006).  A Phase 1 trial to 
determine the safety, tolerability, pharmacokinetics and pharmacodynamics of IRL1620 
(known as SPI-1620 licensed by Spectrum Pharmaceuticals) in patients with recurrent 
progressive carcinoma has been successfully completed and shown to selectively and 
transiently increase tumour blood flow (Gulati et al., 2012; www.cancer.gov/clinicaltrials) .  
A phase II trial was initiated in 2013 to determine the effectiveness of SPI-1620 in 
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combination with docetaxel in patients with advanced biliary cancer 
(http://clinicaltrials.gov/ct2/show/NCT01773785) and in combination with docetaxel 
compared with docetaxel alone for patients with non small-cell lung cancer after failure of 
platinum-based chemotherapy (http://clinicaltrials.gov/show/NCT01741155). 
 
ETB agonists in neuroprotection 
The human brain contains the highest density of ET receptors, with the ETB sub-type 
comprising about 90%, in areas such as cerebral cortex (Harland et al. 1998).  Binding and 
functional studies have demonstrated glia mainly express ETB whereas ETA are localised 
mainly on neurones (Morton and Davenport, 1992).  Smooth muscle cells from large arteries 
and small intracerebral cerebral only express ETA receptors (Adner et al. 1994; Harland et al. 
1995; Pierre and Davenport, 1999) with endothelial cell ETB receptors mediating relaxation 
(Lucas et al.  1996).  The small pial arteries and arterioles penetrating into the brain play a 
major role in the maintenance of cerebral blood flow (autoregulation). These vessels are 
particularly sensitive to ET-1 compared to peripheral vessels and the peptide has been a long 
standing candidate in the genesis or maintenance of cerebrovascular disorders such as 
delayed vasospasm associated with subarachnoid haemorrhage or stroke.  ET-1 does not 
cross the blood brain barrier from the plasma, but may do so when compromised by 
subarachnoid haemorrhage, stroke or head injury.  Strategies for targeting cerebrovascular 
disease have focused previously on the use of ET receptor antagonists, firstly to block 
vascular receptors mediating cerebrovasospasm that may be responsible for delayed cerebral 
ischaemia seen after aneurysmal subarachnoid haemorrhage and could contribute to  
ischaemic core volume in stroke.  Secondly, to block neural receptors that mediate increases 
in intracellular free calcium (Morton and Davenport, 1992) and initiate the 
pathophysiological processes leading to neuronal death. 
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A new emerging strategy is to use ETB agonists such as IRL1620 to provide 
vasodilatation and neuroprotection.  The peptide reduced neurological damage following 
permanent middle cerebral artery occlusion in rats, a model of focal ischaemic stroke.  
Animals received intravenous injections of IRL1620 post occlusion which dramatically  
reduced infarct volume (by more than 80% in the acute and 70% in the chronic study), 
prevented cerebral oedema, reduced oxidative stress markers and improved all neurological 
and motor function for up to seven days (Leonard et al., 2011, 2012, 2013).  Rats treated with 
the amyloid peptide Aβ1-40 administered into the intracerebral vessels increased markers of 
oxidative stress in the brain.  IRL1620 significantly reduced oxidative stress and importantly 
the cognitive impairment (Briyal et al., 2014).  As discussed below, a reduction in ECE 
activity is associated with accumulation of amyloid β-peptide and neurotoxicity early in 
progression of Alzheimer’s disease (Eckman et al., 2001, 2003, 2006, Pacheco-Quinto and 
Eckman, 2013).  These results are limited to disease models in a single species and it is 
unclear whether the molecular mechanisms would translate to humans, but taken together 
they suggest that an ETB agonist might offer a new therapeutic strategy in Alzheimer’s 
disease and provide neuroprotection following cerebral ischemia in conditions such as stroke. 
 
No evidence for further ETB receptor sub-types 
Previous studies have suggested that ETB receptors could be further sub-divided into ETB1 
present on endothelial cells and ETB2  on smooth muscle cells.  Studies continue to be 
published with this misleading nomenclature but current evidence only supports the existence 
of two sub-types, ETA and ETB, according to NC-IUPHAR nomenclature (Davenport 2002; 
Alexander et al., 2013).  Firstly, Mizuguchi et al. (1997) demonstrated unequivocally that in  
ETB receptor knockout mice both the direct constrictor and indirect vasodilator responses to 
the ETB agonist sarafotoxin S6C were abolished.  Selective deletion of endothelial ETB 
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receptors in mice (demonstrated by autoradiography to leave unaltered ETB receptors 
expressed by other cell types) impaired, as expected, the clearance of an intravenous bolus of 
labelled ET-1 compared with controls (Bagnall et al., 2006; Kelland et al., 2010).  Secondly, 
Flynn et al. (1998) were unable to distinguish pharmacologically, in extensive competition 
binding experiments, between ETB receptors expressed by human isolated endothelial 
compared with smooth muscle cells in culture.  In concordance, saturation binding assays in 
human tissue always found ETB radiolabelled ligands bound with a single affinity and Hill 
slopes close to unity with no suggestion of further sub-types (Molenaar et al., 1992, 1993; 
Nambi et al., 1994) or in competition binding versus radiolabelled ET-1 in human native 
(Peter and Davenport 1995, 1996; Russell and Davenport, 1996) or recombinant ETB 
receptors (Nambi et al, 1994; Reynolds et al., 1994). Clozel and Gray (1997) showed that 
endothelial and smooth muscle ETB receptors cannot be distinguished functionally.  
 
Do ETs interact with any other G protein-coupled receptors? 
The virtually complete sequencing of the human genome has allowed the identification of all 
of the human gene sequences that could potentially encode G protein-coupled receptors that 
are currently classified as ‘orphan’ to indicate their endogenous ligand is not yet known 
(Foord et al., 2005; Davenport et al., 2013).  In this catalogue, the most closely related to the 
ETA and ETB sub-types are the orphan receptors GPR37 (also know as endothelin receptor 
type B-like or Parkin-associated endothelin receptor-like receptor) and its related receptor 
GPR37L1.  A recent high throughput screen tested ~10,000 biologically active compounds 
for binding to 82 remaining orphan GPCRs.  None of the ~ 20 ET peptides tested at high 
concentration (including all three mature isoform and their corresponding big ET precursors, 
C-terminal metabolites, BQ123 and the ETB agonist BQ3020) activated any of the expressed 
receptors, including GPR37 or GPR37L, supporting the established concept of ETs binding to 
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only two receptor sub-types.  Two orphan neuropeptides, prosaptide and prosaposin have 
recently been proposed as cognate ligands for GPR37 and GPR37L (Meyer et al., 2013). 
 
 
Clinical application of ET antagonists 
Bosentan, ambrisentan and withdrawal of sitaxentan 
PAH is a progressive condition with no cure and a major impact on the ability to lead a 
normal life.  It is an orphan disease (~100,000 patients in US and Europe).  PAH involves 
constriction of pulmonary arteries and is characterised by high blood pressure in the lungs, 
ultimately leading to right heart failure and death.  A number of pathways have been 
implicated in the development of PAH including bone morphogenetic proteins, prostacyclin 
and ET-1.  Restoring the imbalance between constriction and vasodilatation of blood vessels 
is the basis for current medical therapies, although the cause of death is right heart failure.  
Although ETA receptors are significantly increased in the right ventricle of patients with PAH 
(Kuc et al., 2014) and in the left ventricle of patients with heart failure (Zolk et al., 1999), 
surprisingly ET antagonists have clinical efficacy in the former but not the latter group 
(Kohan et al. 2012). 
Bosentan (Tracleer, Ro47-0203) was the first ET antagonist to be introduced into the 
clinic for the treatment of PAH (Rubin et al., 2002) and as an orally acting agent, at the time 
represented a major advance over existing therapies such as prostacyclin analogues.  
Bosentan is classified as a mixed ETA/ETB antagonist blocking both receptors (Figure 2 and 
3).  The second antagonist to enter the clinic in 2007 was ambrisentan (Letairis, Volibris, 
LU208075, Figure 2 and 3) reported to display some ETA selectivity (Vatter et al., 2006) 
followed by the most highly selective ETA selective antagonist sitaxentan (Thelin, 
TBC11251) (Barst et al. 2004).  While hepatotoxicity is a known side effect of ET 
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antagonists it is usually reversible and related to dose.  Unfortunately, cases of idiosyncratic 
hepatitis resulting in acute liver failure leading to death have been reported with sitaxentan 
and the compound was withdrawn in 2010 (Don et al., 2012). 
 
Next generation of ET antagonists: macitentan 
Despite the current use of ET receptor antagonists and drugs targeting the two other principal 
pathways nitric oxide (phosphodiesterase-5 (PDE5) inhibitors) and prostacyclin (PGI2), 
meta-analysis of PAH trials shows existing therapies only moderately increased the most 
widely used objective evaluation of functional exercise capacity (6-Minute Walk Distance) 
by 11%.  The prognosis for PAH patients remains poor with ~15% mortality within one year.  
There remains an urgent need for new efficacious treatments that has lead to the development 
of macitentan. 
Macitentan (Opsumit, ACT-064992, Figure 2 and 3) represents the next generation of 
orally active ET antagonist and was developed by modifying the structure of bosentan to 
improve efficacy and tolerability (Bolli et al., 2013).  Macitentan (ACT-064992) is described 
as a dual antagonist that blocks both ETA and ETB receptors.  Macitentan (ACT-064992) 
inhibited [
125
I]-ET-1 binding to human recombinant ETA receptors with an IC50 of 0.2 nM 
and 391 nM at ETB receptors.  On the basis of these results, macitentan displays about 800 
fold selectivity.  A Phase III clinical trial was successfully completed in 2012 (Pluido et al., 
2013) and the compound gained approval from the U.S. Food and Drug Administration in 
2013 for the treatment of PAH.  Macitentan is metabolised by the cytochrome P450 system, 
predominantly CYP3A4 and to a lesser extent the CYP2C19 iso-enzyme.  Unlike other 
antagonists in current use one of the metabolites of macitentan, ACT-132577 (Figure 2), is 
pharmacologically active.  Although it has a lower potency than the parent compound ACT-
132577 reaches higher plasma concentrations, with a longer half-life of about 48 hours 
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(Iglarz et al., 2008; Sidharta et al., 2011, 2013a, b).  These factors are likely to contribute to 
improved activity of macitentan compared with bosentan.  Whilst in vitro studies suggested 
macitentan (ACT-064992) was likely to interact with other drugs (Weiss et al., 2013), other 
observed pharmacokinetic benefits included fewer interactions with other drugs at clinically 
used concentrations, no requirement to alter doses in patients with renal or hepatic 
impairment, improved hepatic safety and reduced oedema/fluid retention compared with 
bosentan.  Key differences were also identified in the pharmacodynamic parameters.  For 
example, in calcium release assays macitentan (ACT-064992)  was more potent (KB= 0.1 
nM) than bosentan (KB =1.1 nM) and had a significantly longer receptor occupancy (17 
minutes compared with 70 seconds) (Iglarz, et al., 2008; Bruderer, et al., 2012a, b, 2013; 
Gatfield et al., 2012).  The authors speculated that the macitentan (ACT-064992)  binding 
site is partially different from the bosentan binding site and that this difference in interaction 
with amino acids in the receptor contributes to the slow receptor dissociation of macitentan 
(ACT-064992), particularly leading to insurmountable antagonism.  A number of clinical 
trials are actively recruiting (Patel and McKeage, 2014) including the use of macitentan for 
the treatment of digital ulcers in systemic sclerosis patients, Eisenmenger Syndrome and 
perhaps the most challenging, in patients with brain tumours (glioblastoma). 
 
Compounds interacting with ET-1 synthesis and metabolism 
Members of the neprilysin-like family of zinc metalloendopeptidases play key roles in the ET 
pathway (Turner et al., 2001; Turner and Murphy, 1996).  Neutral endopeptidase (neprilysin, 
NEP) is a membrane bound thermolysin-like zinc metalloendopeptidase which is particularly 
abundant in human kidney.  The enzyme metabolises a number of peptides including 
enkephalins, tachykinins, natriuretic peptides as well as ETs (Turner and Tanzawa, 1997).  
Inactivation of ET-1 is via a two stage process, opening of the Ser
5
-Leu
6
 bond, followed by 
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cleavage at the amino side of Ile
19
 resulting in an inactive peptide, which is inhibited by 
phosphoramidon (Skolovsky et al., 1990).  Pharmacological intervention in the pathway is 
challenging because NEP-like enzymes also include the synthetic enzymes ECE-1, ECE-2 
and KELL.  The ECEs are also inhibited by phosphoramidon and ECE inhibitors currently in 
clinical trials have significant NEP inhibitory activity and it seems counter-intuitive to inhibit 
the degradative pathway.  In practice however, inactivation of ET-1 is thought to be mainly 
via binding and internalization of the ETB receptor and ET-1 is essentially stable in plasma.  
Binding to ETB receptors, particularly in those organs such as the lung expressing high 
densities of the sub-type, are critical for inactivation of the peptide. After internalization of 
the ligand-receptor complex to the lysosome ET-1 is thought to be degraded, like other 
peptides, by cathepsin A.  In support, cathepsin A knock-out mice showed reduced ET-1 
degradation and significantly increased arterial blood pressure.  In humans, genetic defects of 
cathepsin A include hypertension and cardiomyopathies (Seyrantepe et al., 2008). 
 
ECE-1  
It is now well established that ET is synthesised in a three step process, with pre-pro-ET-1 
initially cleaved by a signal peptidase to proET-1, which is in turn cleaved by a furin enzyme 
to an inactive precursor big-ET-1 (Figure 1). Although small molecule inhibitors of furins 
have been reported, furins cleave a number of other proteins to mature or active forms and 
therefore are not an easy tractable drug target for selectively reducing ET-1, without altering 
other pathways.  More promising has been to target the ECE enzymes responsible for 
transformation of big ET-1 to the mature, biologically active ET-1 (Xu et al., 1994; Turner 
and Murphy, 1996).  In humans there are four isoforms, ECE-1a-d, derived from a single 
gene by the action of alternative promoters.  Structurally, they differ only in the amino acid 
sequence of the extreme N-terminus.  ECE-1 localises to the small secretory vesicles of the 
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constitutive pathway from where ET-1 is continuously released to maintain normal vascular 
tone.  Unusually for vasoactive peptides, ET-1 is also synthesised by ECE-1 and stored in 
specialized Weibel-Palade bodies within endothelial cells until released following an external 
physiological or pathophysiological stimulus (the regulated pathway) to produce further 
vasoconstriction (Russell et al., 1998a, b; Russell and Davenport, 1999b). 
In addition to intracellular endothelial cell ECE, the enzyme is also present on vascular 
smooth muscle, efficiently converts big ET-1 in human vessels in vitro and is upregulated in 
atherosclerosis (Maguire et al., 1997; Maguire and Davenport, 1998).  Given the larger 
volume of the smooth muscle compared with single layer of endothelium, smooth muscle 
ECE may be a more important source of ET-1 in pathophysiological conditions. 
 
ECE-2 
ET-1 is also synthesized by a second membrane-bound metalloprotease, ECE-2 (Emoto and 
Yanagisawa, 1995; Lorenzo et al., 2001, Yanagisawa et al., 2000) with ~60% sequence 
similarity to ECE-1.  It is distinguishable from ECE-1 by having an optimum pH of 5.5 for 
activity.  In human endothelial cells ECE-2 was found to be localised to the acidified 
environment of vesicles of secretory pathway, but unlike ECE-1 it is not found in storage 
granules (Russell and Davenport, 1999b).  Four isoforms exist, differing in their N-terminus: 
ECE-2a-1 and ECE-2a-2 are expressed predominantly in peripheral tissues and ECE-2b-1 
and ECE-2b-2 in the brain, possibly representing the neuronal isoforms (Ikeda et al. 2002).  
The physiological importance of this pathway for ET-1 synthesis remains to be determined 
(ECE-2 also metabolises other peptides such as bradykinin), but the requirement for an acidic 
pH suggests a role in pathophysiological conditions associated with low pH such as ischemia.  
ECE-1/ECE-2 knock-put mice display increased developmental defects compared with 
deletion of ECE-1 or ECE-2. 
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Alternative, non-ECE synthetic pathway: chymase 
ET-1 can also be synthesised indirectly by chymase, a serine protease present in mast cells.  
Big ET-1 is converted to ET-11–31 by cleaving the Tyr
31–Gly 32 bond (Figure 1), which in turn 
is converted to the mature peptide via Trp
21–Val22 bond (Fecteau, et al., 2005; D'Orleans-
Juste et al., 2008).  The existence of an alternative pathway was originally predicted when 
ET-1 and ET-2 was detected in embryos of the ECE-1/ECE-2 double-knock-out mouse 
(Yanagisawa et al., 2000). 
The importance of this alternative pathway remains unclear but importantly ET-11–31 was 
equipotent compared with big ET-1 in causing vasoconstriction in human isolated vessels, 
including coronary arteries, and this was associated with the appearance of measurable levels 
of ET-1 in the bathing medium.  ET-11–31 displayed no selectivity between ETA and ETB 
receptors in human heart and vasoconstriction was fully blocked by ETA selective 
antagonists, reflecting the predominance of the ETA receptor on vascular smooth muscle 
(Maguire et al., 2001, 2004).  The precise physiological role of mast cells within human 
blood vessels is unclear but following degranulation, which may occur under 
pathophysiological conditions, the mast cell chymase is associated with interstitial spaces 
with the potential to convert circulating big ET-1 and provide a further source of ET-1.  Mast 
cell expression is increased in cardiovascular disease, for example in atherosclerotic lesions.  
It is therefore possible that the contribution of this pathway within the vasculature, leading to 
over-expression of ET-1, may be underestimated particularly in conditions of endothelial 
malfunction where opposing levels of endogenous vasodilators may be reduced.  It is unclear 
whether under conditions of NEP/ECE inhibition the rising levels of big ET-1 would favour 
increased conversion by the serine protease pathway, thus increasing the pressor effect via 
ETA receptors or whether excretion of unmetabolised big ET-1 by the kidney would be 
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sufficient to remove the elevated levels of precursors (Johmstrom et al., 2010). 
 
KELL and ET-3 synthesis 
Although big ET-3 is converted by ECE-1 to ET-3, owing to difference in the C-terminus the 
efficiency is much less than for ET-1.  In contrast, big ET-3 is reported to be efficiently 
converted by Kell (Lee et al., 1999).  Kell is a membrane bound glycoprotein expressed in 
human erythrocytes and one of the major antigens; it is also related to mammalian NEP-like 
enzymes including ECE-1 and ECE-2 (Turner and Tanzawa, 1997).  If Kell is the main 
synthetic pathway for ET-3, a possible benefit of inhibiting ECE would be to increase the 
ratio of ET-3 to ET-1, which could then differentially produce beneficial vasodilatation via 
the ETB receptor, but this speculative hypothesis has not been tested. 
 
Pharmacological inhibition of ECE by research compounds 
A combination of phosphoramidon and thiorphan has been widely used to identify ECE 
activity.  This is based on demonstrating that the conversion of big ET-1 to ET-1 is inhibited 
by phosphoramidon, but not by thiorphan, and has been shown both in vitro and in vivo.  
Importantly for evaluating the significance of animal models, both compounds have also been 
used in clinical studies to characterise big ET-1 conversion (see for example, Webb, 1995; 
Plumpton, et al. 1995; Hand et al., 1999).  Small molecule, non-peptide ECE inhibitors have 
been developed; one that has been widely used in vitro and in vivo animal models and is 
commercially available is CGS26303 (De Lombaert et al., 1994).  CGS26303 has been 
shown experimentally to significantly inhibit conversion of all three big-ETs in human 
isolated vessels but importantly does not interfere with the interaction of mature peptides 
with ET receptors (Yap et al., 2000).  Although primarily an NEP inhibitor, SOL1, a more 
recent combined NEP/ECE non-peptide inhibitor with modest inhibition of ECE-1 in vitro, 
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was remarkably potent in vivo, fully blocking the big-ET-1-induced rise in blood pressure at a 
dose of 10 μmol kg-1 (Nelissen et al., 2012). 
A disadvantage of using phosphoramidon is that it there is of course the possibility of 
significant inhibition of NEP and any pharmacological actions may also be mediated via 
inhibition of degradation of other peptides such as ANP.  An alternative tool compound is 
PD159790, which inhibits ECE-1 with an IC50 value of 3 M; at this concentration the 
compound is selective for ECE-1 over NEP (Ahn et al., 1998).  PD159790 has been shown 
experimentally in human umbilical vein endothelial cells to inhibit conversion of big ET-1 at 
pH 6.9, optimum for ECE-1, but did not affect big ET-1 conversion to the mature peptide at  
pH 5.4, optimum for ECE-2 (Russell and Davenport, 1999a).  The compound did not inhibit 
the further metabolism of ET-11 - 31, the chymase product of big ET-1 (Maguire et al.  2001) 
and can be used to distinguish between the three different pathways for ET synthesis.  While 
the mature peptide is located to intracellular Weibel-Palade bodies or secretory vesicles 
within endothelial cells and a proportion of big ET-1 is converted to ET-1 intracellularly, it is 
not reported whether ECE inhibitors can cross the plasma membrane to access these 
intracellular sites.  The main effects of these inhibitors may be on external ECE: in agreement 
with this proposal, the SLV306 metabolite KC-12615 (see below) effectively prevented 
conversion of exogenous big ET-1 in human vasculature (Seed et al., 2012). 
 
Emerging NEP/ECE inhibitors 
Selective inhibitors of ECE have not progressed into clinical applications.  SLV306 
(Daglutril, Figure 2) is an orally active, mixed enzyme inhibitor of both ECE and NEP.   It is 
a pro-drug being converted in vivo to an active metabolite, KC-12615. This latter molecule 
has a pharmacological profile similar to phosphoramidon, inhibiting NEP in the nanomolar 
range but with more modest inhibition in the micromolar range for ECE (Meil et al., 1998; 
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Jeng et al., 2002)   The therapeutic basis is that while inhibition of NEP alone increased 
plasma concentrations of ANP to cause vasodilatation, NEP inhibitors are ineffective as anti-
hypertensives, probably because NEP also degrades vasoconstrictor peptides including ET.  
A combined ECE/NEP inhibitor would be predicted to reduce the systemic conversion of big 
ET-1 to the mature peptide and increase dilator peptides such as ANP.  SLV306 has been 
reported to be well tolerated with few or none of the side effects such as increases in liver 
function, oedema, observed with ET receptor antagonists (Dickstein et al., 2004; Parvanova 
et al. 2013).  A potential disadvantage is big ET-1 might still be converted to ET-1 by an 
alternative pathway such as chymase.  However, in animal models with normal renal 
function, this does not occur: big ET-1 labelled with the positron emitter 
18
F was rapidly 
accumulated unchanged in the kidney following inhibition of NEP/ECE, with no evidence of 
conversion by another pathway (Johnström et al., 2010). 
The effect of a combined NEP/ECE inhibitor has been tested in volunteers in a 
randomised, double blinded trial.  Following oral administration of three increasing doses of 
SLV306 (to reach an average target concentration of 75, 300, 1200 ng ml
-1
 of the active 
metabolite KC-12615), big ET-1 was infused into thirteen male volunteers at a rate of 8 and 
12 pmol kg
-1
min
-1 
(20 min each).  At the two highest concentrations tested, SLV306 dose 
dependently attenuated the rise in blood pressure after big ET-1 infusion.  There was a 
significant increase in circulating big ET-1 levels compared with placebo, indicating that 
SLV306 was inhibiting an increasing proportion of endogenous ECE activity. Importantly, 
plasma ANP concentrations also significantly increased, consistent with systemic NEP 
inhibition (Seed et al.,  2012). 
 
SLV306 in animal models and patients with type 2 diabetes and nephropathy 
Diabetes causes activation of the renal endothelin system which leads to progressive renal 
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damage by cell proliferation and interstitial inflammation.  Inhibitors of the renin–angiotensin 
system are widely used in treatment for hypertensive patients with type 2 diabetes but are less 
effective in the advanced stages of diabetic renal disease.  Studies suggested in an animal 
model that SLV306 had a similar efficacy to the angiotensin enzyme inhibitor captopril in 
reducing proteinuria and preventing nephrosclerosis (Thöne-Reinke et al. 2004).  In this 
study, rats were treated with streptozotocin for twenty weeks and the effects of SLV306 (30 
mg kg
-1
 per day) compared with captopril (10 mg kg
-1
 per day).  SLV306 significantly 
decreased renal interstitial matrix content as well as protein and albumin excretion in diabetic 
rats, independent of blood pressure and was as effective as captopril.  These results suggested 
SLV306 treatment on top of blocking the rennin-angiotensin system might have additional 
benefit in reducing blood pressure and improving renal function. 
Parvanova et al. (2013) tested the efficacy of SLV306 in 45 patients with type 2 diabetes 
mellitus who had albuminuria, on top of the angiotensin receptor antagonist losartan together 
with up to two additional anti-hypertensive drugs, in a randomised, crossover, double-blind, 
placebo controlled trial.  Although eight weeks of treatment with SLV306 together with 
losartan did not significantly alter urinary albumin excretion or renal haemodynamic 
measures, the authors showed for the first time the combination decreased ambulatory blood 
pressure (particularly for systolic hypertension) in this patient group that are often resistant to 
treatment.  There was a small but significant increase in plasma big ET-1, consistent with 
ECE inhibition, but surprisingly not in proANP; increases in the natriuretic peptides was 
measured in healthy volunteers by Seed et al, (2012).  Interestingly, the effect of SLV306 in 
this study on blood pressure was higher at night (10 versus 12 mm Hg).  This is of potential 
importance since increased hypertension at night is a strong cardiovascular risk factor in this 
patient population.  The molecular mechanism is not yet known, as plasma levels of big ET-1 
were not reported separately for day time versus night.  The study was comparatively short 
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and did not reveal significant changes in albumin excretion as predicted from animal studies; 
long-term trials are required to determine whether the observed lowering of blood pressure by 
SLV306 will translate into longer term renal and cardio-protection. 
 
SLV306 and congestive heart failure 
The effect of three single oral doses of SLV306 was tested in patients with congestive heart 
failure who underwent right-sided heart catheterization in a randomized, double-blind, 
placebo-controlled design (Dickstein et al.,  2004).  Pulmonary pressures and right atrial 
pressure decreased significantly in all SLV306 dose groups with the maximum decrease 
occurring at 6 to 8 hours.  Despite plasma levels of the drug increasing with dose, there was 
no clear dose-response relationship which may have been the result of the comparatively 
small numbers (18-20) in the study. 
 
Insight on NEP/ECE inhibition from animal models 
The efficacy of inhibiting NEP/ECE in animal models associated with increases in the ET 
signalling pathway has provided clues to future clinical applications.  The development of 
nephropathy in diabetes is associated with a poor outcome, eventually leading to end-stage 
renal disease.  In diabetic patients urinary excretion of protein and albumin rises and is 
associated with increased risk of cardiovascular disease.  In diabetic rats, SLV306 decreased 
renal matrix protein content, protein and albumin excretion.  The magnitude of these effects 
was comparable to angiotensin converting enzyme inhibition and independent of blood 
pressure (Thöne-Reinke et al., 2004).  Currently there are few drugs for the treatment of 
chronic renal failure.  SLV338, a NEP/ECE-inhibitor, abolished renal tissue damage 
(interstitial fibrosis, glomerulosclerosis, renal arterial remodelling) in a rat models of both 
acute kidney failure as well as chronic renal failure.  The compound preserved kidney 
 27 
function and reduced mortality (Sharkovoska et al., 2011).  In spontaneously hypertensive 
stroke-prone rats SLV338 significantly improved survival in comparison to the vehicle 
treated group in a blood pressure-independent manner and could offer a new therapeutic 
approach for primary stroke prevention and improvement of mortality (Wengenmayer et al., 
2011).  SLV338 was also tested for cardiac protection in rat model of experimental 
renovascular hypertension (2-kidney, 1-clip).  SLV338 prevented cardiac remodelling to the 
same extent as losartan, but in a blood pressure-independent manner.  This effect is at least 
partially mediated via suppression of cardiac transforming growth factor-β1 expression (Kalk 
et al., 2011). 
ET has been proposed to be a mediator in toxic liver injury.  However, while SLV338 
largely prevented the activation of the ET system it did not prevent D-galactosamine-induced 
acute liver injury in rats.  The authors speculated that SLV388 should be tested in a less 
severe model of liver injury, since very severe intoxication might not be relevantly amenable 
to pharmacological interventions (Hocher et al., 2011). 
 
ECE-1 and amyloid deposition 
The strategy in cardiovascular and renal systems has been to inhibit ECE-1 activity.  
However, evidence is emerging that ECE-1 may function in the brain as a novel enzyme 
degrading amyloid β-peptides at multiple sites.  Deposition of amyloid in the brain in 
Alzheimer's disease is determined not only by its production but also by its catabolism.  ECE-
1 inhibition produces, in addition to extracellular accumulation, intracellular amyloid β-
peptides accumulation within endosomal/lysosomal and autophagic vesicles and an 
intracellular pool is partly regulated by ECE activity at the sites of production.  Reduction in 
ECE activity leads to accumulation of amyloid β-peptide which is associated with 
neurotoxicity early in progression of Alzheimer's disease (Eckman et al., 2001, 2003, 2006; 
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Pacheco-Quinto and Eckman, 2013).  The clearance of Aβ1-40 in mice was almost completely 
inhibited by phosphoramidon as well as insulin indicating that human Aβ1-40 was degraded, at 
least in part, by a phosphoramidon-sensitive pathway, implicating both ECE and NEP (Ito et 
al., 2013). 
To date these investigations have comprised in vitro or in vivo rodent studies  It is not yet 
clear whether enhancing ECE-1 activity is a potential drug target in Alzheimer’s rather than 
inhibiting ECE-1, as in the periphery.  ECE-like immunoreactivity has been localised to 
afferent and efferent fibres of neurones and neuronal cell bodies of mixed morphology in 
human brain (Giaid et al., 1991).  Drugs increasing ECE activity such as enzyme enhancers 
or recombinant ECE would have to cross the blood brain barrier and it is not clear what effect 
this would have on the peripheral ET signalling. 
 
What are the new ET drug targets in the future? 
Epigentics 
Epigenetics can be defined as heritable changes in phenotype through mechanisms other than 
changes in DNA sequence.  Epigenetic changes will therefore be preserved when cells divide 
and affect normal development and disease progression.  Processes mediating epigenetic 
regulation include DNA methylation and histone modification which involves post-
translational covalent modification of histone proteins by a range of writers, erasers and 
readers.  This in turn modulates the ability of associated DNA to be transcribed.  The histone 
code is read by specific families of proteins such as the bromodomains.  These are of 
pharmacological significance because of the recent discovery of small molecule inhibitors, 
which selectively modulate gene expression (Prinjha et al., 2012). 
Epigenetic regulation is of particular importance in the ET pathway with transcription 
being the primary level of ET-1 regulation of the gene EDN1 by histone modifications and 
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DNA methylation (Welch et al., 2012).  Silencing of the EDNRB gene by DNA methylation 
during development of tumours results in the down-regulation of the receptor.  As a result, 
promotion of apoptosis via the ETB receptor is reduced or lost, suggesting the ETB receptor 
could be a target for epigenetic drugs or ETB agonists where ET may be the cause of some 
tumour types, including melanomas and oligodendrogliomas (Bagnato et al., 2011).  
Intriguingly, epigenetic inactivation of ET-2 and ET-3 mRNA and protein was found in rat 
and human colon tumours and cancer cell lines, as a result of hypermethylation of EDN2 and 
EDN3 genes.  Restoring expression of ET-2 and ET-3 in human cells significantly attenuated 
the migration and invasion of human colon cancer cells (Wang et al., 2013).  Since ET-3 
displays high affinity for the ETB receptor, forced expression of ET-3 might antagonise the 
actions of ET-1 mediated through ETA receptors. Such a mechanism would be consistent with 
proposed beneficial effects of IRL-1620, the ETB agonist in cancer. 
 
Life before birth – is ET a critical pathway? 
Maternal malnutrition and uteroplacental vascular insufficiency causes foetal growth 
restriction or intrauterine growth retardation.  Low birth weight is linked to the later 
development of cardiovascular disease and hypertension.  Maternal treatment with 
dexamethasone increased ET-1 constrictor responses and ETA receptor expression in 
placental arteries from the foetus (Kutzler et al., 2003; Docherty et al., 2003). Recently, Xu 
(et al., 2103) have shown maternal nutrient restriction increased the histone acetylation and 
hypoxia inducible factor-1α (HIF-1α) binding levels in the ET-1 gene promoter of  growth 
restricted newborn rats, which continued to 6 weeks after birth. The authors speculate that   
that this intrauterine growth retardation could  cause varying degrees of  PAH later in life.  
Biased signalling in the ET pathway 
Pharmacology is undergoing a revolution in understanding the mechanism of ‘biased 
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signalling’ via G protein-coupled receptors.  It was originally thought that ligands binding to 
a receptor would equally activate the G protein pathway to produce a physiological response 
such as vasoconstriction (such as ET-1 acting on an ETA receptor) as well as activating the -
arrestin pathway which eventually leads to desensitisation, receptor internalization and 
‘silencing’ of the pathway.  It is now clear that some ligands are biased to one pathway over 
the other and secondly, rather than silencing, -arrestin can activate alternative signalling 
pathways, some of which may be pathophysiological leading to longer term signalling 
responses such as migration and proliferation. 
Both ET receptor subtypes follow an -arrestin and dynamin/clathrin-dependent 
mechanism of internalization, but it has been established that ETA are recycled to the plasma 
membrane for further signalling while ETB are targeted to lysosomes and degraded (Bremnes 
et al., 2000).  In epithelial ovarian cancer, activation of ET-1/ETA receptor signalling is 
linked to many tumour promoting processes including proliferation, angiogenesis, invasion 
and metastasis.  NF-κB is an important signalling molecule in immunity, inflammation and 
cancer and β-arrestin is required for ET-1-induced NF-κB activation (Cianfrocca et al., 
2014).  ET-1 promoted podocyte migration via ETA receptors and increased β-arrestin-1, 
sustaining renal injury, a pathogenetic pathway that can affect podocyte phenotype in 
proliferative glomerular disorders (Buelli et al., 2014).  β-Arrestin-1 has also been found to 
be a nuclear transcriptional regulator of ET-1-induced β-catenin signalling, an important 
mechanism for controlling cell division and progression of epithelial ovarian cancer and 
necessary for epigenetic modification, such as histone acetylation, and gene expression 
(Rosanò et al., 2013, 2009).  In addition these effects are blocked by ET receptor antagonists 
and support a role for ETA-mediated/β-arrestin-1 facilitating inter-protein interaction in 
invasive and metastatic behaviour of ovarian cancer. 
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Biased ET ligands? 
Agonists have been identified that are biased towards β-arrestin signalling for parathyroid 
hormone and AT1 receptors.  G protein pathway-selective agonists have been identified for 
nicotinic acid and μ opioid receptors (Luttrell, 2014).  The race is now to determine whether 
such strategies can be exploited therapeutically. 
Do biased ligands (ligands that binding to the same receptor but activate different 
signalling pathways) exist for ET receptors?  The study by Compeer et al. (2013) already 
mentioned suggested ET-1 and ET-2 initiate and maintain vasoconstriction by different 
downstream mechanisms.  Biased signalling can be identified by comparing the affinities of 
ligands in β-arrestin recruitment assays with a G protein mediated response such as 
vasoconstriction (Maguire et al., 2012). In this study the rank order of potency for β-arrestin 
recruitment at the ETA (ET-1≥ET-2>>ET-3) and ETB (ET-1=ET-2=ET-3) receptors was as 
expected and there was no obvious major differences in potency of ETs when comparing with 
G protein mediated constrictor assays in human vessels.  However, at the ETA receptor 
sarafotoxin S6b was a partial agonist in β-arrestin recruitment but a full agonist in causing 
constriction, suggesting the possibility of biased ligands.  Such a bias could have been 
selected for during evolution by prolonging the effects of envenomation of the mammalian 
prey.  While bosentan displays no selectivity for ETA over ET receptors in radioligand 
binding and G protein functional assays, unexpectedly it was significantly more effective an 
inhibitor of β-arrestin recruitment mediated by ETA compared to the ETB receptor (Maguire 
et al., 2012).  The result for bosentan is intriguing since many of the detrimental actions of 
ET-1, particularly in cancer, may use the β-arrestin pathway and this suggests the potential to 
block a deleterious pathway whilst preserving activation of a beneficial pathway. 
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The next twenty-five years –quo vadis? 
Since the discovery of ET intense medicinal chemistry programmes have identified receptor 
antagonists, ETB receptor agonists and inhibitors of the key synthetic enzyme, ECE-1.  Both 
mixed ETA/ETB and ETA selective antagonists have become established in the treatment of 
PAH, while NEP/ECE inhibitors such as SLV306 have promise as an alternative to receptor 
blockage and IRL1620 and other ETB analogues have potential in improving cancer therapy. 
All of these are approaches that have exploited small molecules.  Over 50 therapeutic 
monoclonal antibodies have been approved for clinical use, but none yet against a GPCR 
target, emphasising the technical challenge.  Endomab-B1, a monoclonal antibody has 
recently been reported to bind with sub-nanomolar affinity for the ETB receptor, competed 
with ET-1 binding with greater efficacy than BQ788, and functions as an antagonist to block 
the ET-1-induced IP3-calcium signalling pathway (Allard et al., 2013).  Whether this 
antibody has clinical applications remains to be discovered. 
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Figure Legends 
Figure 1.  Schematic diagram illustrating synthesis of ET peptides and interaction with 
receptors. 
 
Figure 2.  Structures of ET receptor antagonists in clinical use bosentan, ambrisentan  and 
macitentan.  The structures of the NEP/ECE inhibitor pro-drug SLV306 and its active 
metabolite are also shown. 
 
Figure 3.  Selectivity of ET receptor antagonists for ETA versus ETB receptors shown on the 
vertical axis as reported by the companies that discovered the compounds.  Selectivity was 
mainly determined by measuring affinity constants in separate competition assays against 
[
125
I]-ET-1 using human recombinant ETA versus ETB receptors and may not reflect 
selectivity measured in clinically relevant native tissues.  Bosentan, ambrisentan and 
macitentan are currently approved for clinical use and are highlighted. 
